Erika P. Berger
Iowa State University
12 Papers
6 Citations
Erika P. Berger is an academic researcher from Iowa State University. The author has contributed to research in topics: Medicine & Cancer. The author has an hindex of 5, co-authored 10 publications. Previous affiliations of Erika P. Berger include Iowa State University College of Veterinary Medicine & National Institutes of Health.
Chat about Author
Papers
Veterinary Cooperative Oncology Group-Common Terminology Criteria for Adverse Events (VCOG-CTCAE v2) following investigational therapy in dogs and cats.
Amy K. LeBlanc,Matthew J. Atherton,R. Timothy Bentley,C. Elizabeth Boudreau,Jenna H Burton,Kaitlin M. Curran,Steven W. Dow,Michelle A. Giuffrida,Heidi B. Kellihan,Nicola J. Mason,Michelle L. Oblak,Laura E. Selmic,Kimberly A. Selting,Ameet Singh,S.S. Tjostheim,David M. Vail,Kristen M. Weishaar,Erika P. Berger,John H. Rossmeisl,Christina Mazcko +19 more
TL;DR: The updated Veterinary Cooperative Oncology Group (VCOG-CTCAE v2 guidelines as mentioned in this paper contain several important updates and additions since the last update (v1.1).
181
Canine and murine models of osteosarcoma
Jessica Beck,Ling Ren,Shan Huang,Erika P. Berger,Kathleen Bardales,Joshua Mannheimer,Christina Mazcko,Amy K. LeBlanc +7 more
TL;DR: In this review, animal models of OS are described with a focus on the mouse and tumor-bearing pet dog as parallel and complementary models of human OS.
39
Retrospective evaluation of toceranib phosphate (Palladia®) use in the treatment of gastrointestinal stromal tumors of dogs.
Erika P. Berger,Chad M Johannes,Albert E. Jergens,Karin Allenspach,Barbara E. Powers,Yingzhou Du,Jonathan P. Mochel,Leslie E Fox,Margaret L. Musser +8 more
TL;DR: Biological activity of toceranib is evident in dogs with gross disease and metastasis of GIST at diagnosis, as well as high tumor mitotic index, was associated with shorter PFI in tocerAnib‐treated dogs.
Adjuvant Sirolimus Does Not Improve Outcome in Pet Dogs Receiving Standard-of-Care Therapy for Appendicular Osteosarcoma: A Prospective, Randomized Trial of 324 Dogs.
Amy K. LeBlanc,Christina Mazcko,Aswini Cherukuri,Erika P. Berger,William C. Kisseberth,Megan E. Brown,Susan E. Lana,Kristen M. Weishaar,Brian K. Flesner,Jeffrey N. Bryan,David M. Vail,Jenna H Burton,Jennifer L. Willcox,Anthony J. Mutsaers,J. Paul Woods,Nicole C. Northrup,Corey F. Saba,Kaitlin M. Curran,Haley Leeper,Heather Wilson-Robles,Brandan G Wustefeld-Janssens,Stephanie S Lindley,Annette N. Smith,Nikolaos Dervisis,Shawna Klahn,Mary Lynn Higginbotham,Raelene M. Wouda,Erika L. Krick,Jennifer A. Mahoney,Cheryl A. London,Lisa G. Barber,Cheryl E. Balkman,Angela L McCleary-Wheeler,Steven E. Suter,Olya Martin,Antonella Borgatti,Kristine Burgess,Michael O. Childress,Janean Fidel,Sara D. Allstadt,Daniel L. Gustafson,Laura E. Selmic,Chand Khanna,Timothy M. Fan +43 more
TL;DR: In this article, the mTOR pathway has been identified as a key nutrient signaling hub that participates in metastatic progression of high-grade osteosarcoma, and inhibition of mTOR signaling is biologically achievable with sirolimus, and might slow the outgrowth of distant metastases.
Retrospective evaluation of toceranib phosphate (Palladia) use in cats with mast cell neoplasia
Erika P. Berger,Chad M Johannes,G. S. Post,Gillian Rothchild,Kai-Biu Shiu,Sarah Wetzel,Leslie E Fox +6 more
TL;DR: Toceranib appears to be well tolerated in feline patients with mast cell neoplasia and biologic activity of this drug is evident in the studied cats; however, further prospective studies are needed to elucidate fully its role in treatment of this disease.
19